DMII director acquires 100,000 shares from sponsor
Drugs Made In America Acquisition II Corp. reported an insider transaction on a Form 4.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Drugs Made In America Acquisition II Corp. reported an insider transaction on a Form 4. Director Catherine Do acquired 100,000 ordinary shares on 09/26/2025 under transaction code J.
According to the footnote, the shares were acquired from the Issuer’s sponsor, Drugs Made In America Acquisition II LLC, for no consideration. Following the transaction, the reporting person beneficially owned 100,000 shares held in direct ownership.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Other | Ordinary shares | 100,000 | $0.00 | $0.00 |
Footnotes (1)
- F1. As of the Transaction Date, the reporting person acquired 100,000 ordinary shares from Drugs Made In America Acquisition II LLC, the Issuer's sponsor, for no consideration.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did DMIIU report?
When did the DMIIU insider transaction occur?
What was the Form 4 transaction code for the DMIIU filing?
What is the reporting person’s relationship to DMIIU?
Was the ownership direct or indirect after the DMIIU transaction?
AI-generated analysis. How Rhea-AI works. Not financial advice.